Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
· 2 h 05 min · Episode 18
Episode Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Dave Ricks, the CEO of Eli Lilly, the world's most valuable pharmaceutical company, sits down with John and Patrick to discuss the complex business of drug development. Dave explains the true origin story of GLP-1s (from Gila monster saliva), why their potential goes far beyond weight loss to addiction and inflammation, and how "self-pay" has become the #1 way new patients get Zepbound. They cover the "shadow generic" industry undermining patents, the challenges associated with clinical trial enrollment, and what drove insulin list prices to $275 (while the net price was $40). This is a rare, candid look into the strategies, science, and future of pharma from one of the industry's most influential leaders.
Timestamps
(00:00) Introducing Dave Ricks
(05:07) Making R&D decisions
(10:10) Clinical trials
(24:59) Drug pricing
(32:43) Stimulating more R&D
(54:15) Pros and cons of US healthcare
(58:20) New pharma business models
(01:05:53) Stripe and enterprises
(01:07:00) China
(01:16:31) Generics
(01:22:37) GLP-1s
(1:37:43) r/Peptides
(01:41:25) LillyDirect
(01:46:35) Why do investors love LLY?
Transcript
Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.